绿萼梅提取物对小鼠的抗抑郁作用

目的：观察绿萼梅提取物对小鼠的抗抑郁作用。方法采用悬尾实验（ TFT）、强迫游泳（ FST）等体内药效评价方法观察绿萼梅醇提取物和水提取物对抑郁模型小鼠的治疗作用。结果绿萼梅醇提物能明显缩短小鼠悬尾和强迫游泳不动时间（ P＜0．05）,且对自主活动无影响（ P＞0．05）;而水提物对小鼠悬尾和强迫游泳不动时间无显著影响（ P＞0．05）。结论绿萼梅乙醇提取物具有抗小鼠抑郁作用。     

A case report on elderly psychotic-like symptoms caused by antidepressant discontinuation

ObjectivesCure for severe depression in elderly patients with psychotic symptoms should consider not only the results of major depression but also the nature of antidepressants and their side effects. Psychiatric disability is higher in patients who have greater deterioration in neurological function.MethodsIn addition to reviewing antidepressant discontinuation syndrome and depressive disorder, this study describes an elderly woman with mild depression that developed into major depression, related to high suspicion of delirium, diagnosed based on patient history, physical health examination, neurological examinations, family history, and laboratory data, with subsequent treatment plan.ResultsThe treatment results and prognosis indicate that patients with paroxetine antidepressant deactivation may enable early use of low-dose quetiapine with less anticholinergic and extrapyramidal side effects for the treatment of depression in elderly patients with psychotic symptoms. The poor prognostic factors for patients were chronic environmental stress (poverty) and lack of a social support system. Although the patient lived with her children and grandchildren, she rarely received care. Hence, it was not possible to monitor her condition and medication intake.ConclusionsThe consensus is that the abrupt discontinuation of short half-life selective serotonin reuptake inhibitors (SSRIs), such as paroxetine can be associated with transient symptomatology, much of which is of a serotonergic nature. Psychotic-like symptoms have also been reported in both controlled trials and large patient databases.     

Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome: A Double-Blind,Randomized, Placebo-Controlled Trial

Background The efficacy of antidepressants in irritable bowel syndrome (IBS) is controversial. No trials have directly compared a tricyclic with a selective serotonin reuptake inhibitor. Our aim was to determine whether imipramine and citalopram are efficacious in IBS. Methods This was a randomized, double-blind, placebo-controlled, parallel group pilot trial with imipramine (50 mg) and citalopram (40 mg). Results Of 51 IBS patients randomized, baseline characteristics were comparable among the treatment arms; the majority was diarrhea-predominant. Adequate relief of IBS symptoms (primary endpoint) was similar for each treatment arm. Improvements in bowel symptom severity rating for interference (P = 0.05) and distress (P = 0.02) were greater with imipramine versus placebo, but improvements in abdominal pain were not. There was a greater improvement in depression score (P = 0.08) and in the SF-36 Mental Component Score (P = 0.07), with imipramine. Citalopram was not superior to placebo. Approximately 20% of the variance in scores was explained by treatment differences for abdominal pain, bowel symptom severity disability, depression and the mental component of the SF-36. Conclusion Neither imipramine nor citalopram significantly improved global IBS endpoints over placebo.     

Brief Clinical Report REDUCTION OF CENTRAL POSTSTROKE PAIN WITH THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FLUVOXAMINE

To investigate the effect of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine on central poststroke pain (CPSP), fluvoxamine (25 to 125 mg daily) was given to 31 patients. Although 3 patients dropped out within 1 week, 28 patients who received fluvoxamine for 2 to 4 weeks showed a significant reduction in the visual analog scale (VAS) for pain from 7.7 &#45 2.2 to 6.0 &#45 3.4 (p <. 01). This improvement in VAS was significant in patients within less than 1 year after stroke, but not in those with a duration of more than 1 year. Zung s Self-rating Depression Scale (SDS) was also significantly improved after treatment, but there was no significant correlation between the changes in VAS and SDS. Although this is not a double-blind, placebo-controlled trial, these results suggest that fluvoxarnine is useful for the control of CPSP regardless of depression when used relatively early after stroke.     

抗抑郁药物治疗幽门螺旋杆菌阴性的慢性胃炎临床观察

目的:探讨抗抑郁药物对幽门螺旋杆菌阴性的慢性胃炎的治疗作用.方法:将298例幽门螺旋杆菌阴性的慢性胃炎患者随机分成对照组和治疗组,对照组140例予以奥美拉唑胶囊治疗,治疗组158例予以奥美拉唑胶囊及抗抑郁药物(氟哌噻吨美利曲辛片)联合治疗4周,然后对两组治疗前后的疗效进行分析.结果:两组治疗后患者的症状改善程度差异有显著性.结论:抗抑郁药物联合质子泵抑制剂对改善幽门螺旋杆菌阴性的慢性胃炎的症状有显著效果,可作为幽门螺旋杆菌阴性的慢性胃炎有效治疗途径之一.     

性病恐怖心理因素治疗2例

目的性病恐怖是性病患者因心理因素而导致心理功能障碍而产生的一系列神经症候群，在给患者进行正常的药物治疗原发病灶外，同时要让患者了解疾病的相关知识。耐心地对其进行心理治疗，并适量使用抗抑郁药物也非常必要。方法病例1曾患性病虽早已治愈，但患者患有手足癣并发慢性复发性丹毒，患者一直误以为性病未愈，加之非皮肤性病专业医生的误导，长期按性病治疗：病例2患者曾有性病，因一些正常生理变化而极度自卑恐惧，进行心理疏导和对症治疗。结果两位患者临床均已痊愈。结论对患有性病恐怖症倾向患者除治疗原发病灶．给予适量抗抑郁药物，加上耐心地对其心理治疗也是取得满意疗效的关键因素。